“…According to the European Guidelines on CVD prevention in clinical practice, targeting patients without clinical symptoms of CVD and with one or several risk factors may give them a benefit from prevention. These patients are, in particular, those who consider themselves 'healthy' and whose risk factors are 'silent' (inconspicuous) and include: central obesity, dyslipidemia, glucose intolerance and high blood pressure, previously described as metabolic syndrome (MetS) [6]. The prevalence of the MetS varies according to the employed definition, population, age and gender, and regardless of the applied definitions is associated with a notably increased risk of CV morbidity and mortality [7].…”